Leerink initiates coverage on Quince with Outperform rating
Leerink Partners analyst Joseph Schwartz has initiated coverage on Quince Therapeutics with an Outperform rating and a price target of $4.
*this image is generated using AI for illustrative purposes only.
Leerink Partners analyst Joseph Schwartz has initiated coverage on Quince Therapeutics with an Outperform rating and a price target of $4. This rating indicates a positive outlook on the company's stock performance potential.
Analyst Details
Joseph Schwartz, an analyst at Leerink Partners, assigned the Outperform rating to Quince Therapeutics. This rating suggests that the stock is expected to outperform the average return of the analyst's coverage universe over the next 12 months.
Price Target
The firm set a price target of $4 for Quince Therapeutics. This target indicates the projected value the analyst believes the stock could reach within a specified timeframe.
| Metric | Value |
|---|---|
| Rating | Outperform |
| Price Target | $4 |
| Analyst | Joseph Schwartz |
| Coverage Firm | Leerink Partners |
What specific catalysts does Leerink Partners anticipate will drive Quince Therapeutics' stock to the $4 price target?
How might Quince Therapeutics' upcoming clinical trial results influence investor sentiment and stock performance?
What competitive advantages does Quince Therapeutics have that could support its outperformance relative to peers?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
